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Background: Human insulin is commonly used to treat hyperglycemia in patients with diabetes, but its potential
link with female breast cancer is under debate. This study investigated whether human insulin use might be associated
with breast cancer risk in Taiwanese women with type 2 diabetes.
Methods: The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the
National Health Insurance. An entry date was set at 1 January 2004 and a total of 482,033 women with type 2 diabetes
were followed up for breast cancer incidence until the end of 2009. Incidences for ever-users, never-users and subgroups
of human insulin exposure (using tertile cutoffs of time since starting insulin, cumulative dose and cumulative duration
of insulin) were calculated and the adjusted hazard ratios were estimated by Cox regression. The potential risk
modification by concomitant treatment with metformin, statin and angiotensin converting enzyme inhibitor/
angiotensin receptor blocker (ACEI/ARB) was also evaluated.
Results: There were 59,798 ever-users and 422,235 never-users of human insulin, with respective numbers of
incident breast cancer of 559 (0.93 %) and 4,711 (1.12 %), and respective incidence of 207.9 and 215.1 per
100,000 person-years. The overall adjusted hazard ratio (95 % confidence interval) did not show a significant
association with insulin [1.033 (0.936-1.139)]. However, patients in the third tertiles of dose–response parameters
might show a significantly higher risk of breast cancer while compared to never-users: 1.185 (1.026-1.368), 1.260
(1.096-1.450) and 1.257 (1.094-1.446) for ≥67 months for time since starting insulin, ≥39,000 units for cumulative
dose of insulin, and ≥21.8 months for cumulative duration of insulin, respectively. Additional analyses suggested
that the breast cancer risk associated with human insulin use might be beneficially modified by concomitant
use of metformin, statin and ACEI/ARB.
Conclusions: This study discloses a significantly higher risk of breast cancer associated with prolonged use of
human insulin. The increased risk of breast cancer associated with human insulin use may be modified by medications
such as metformin, statin and ACEI/ARB.
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Diabetes mellitus may increase the risk of breast cancer
in terms of incidence and mortality [1, 2]. However,
whether insulin use can be responsible for the increased
risk of diabetes-related breast cancer is still under
debate. Some in vitro and observational studies provide
evidence for a potential link between insulin and breast
cancer. For examples, insulin can be found in human breast
cancer tissues [3], and some breast cancers are responsive
to insulin and administration of insulin/insulin-like growth
factor 1 (IGF-1) receptor family kinase inhibitor or alloxan
to produce a status of hypoinsulinemia by destroying
the insulin producing pancreatic β-cells may inhibit
tumor growth of breast cancer cell line [4]. Mammalian
target of rapamycin (mTOR) is activated by insulin and
insulin-mediated breast cancer progression in patients
with type 2 diabetes mellitus may be abrogated by
inhibition of mTOR [5]. The Women’s Health Initiative
study prospectively showed that elevated insulin level
may predict postmenopausal breast cancer [6].
Insulin glargine, a long-acting insulin analog, has a
6- to 8-fold higher binding affinity to IGF-1 receptor
than human insulin [7]. Insulin glargine may stimulate
the proliferation of breast cancer cell lines [8, 9]. A
recent nested case–control study suggested that insulin
glargine may increase the risk of all cancer, while
human insulin and other types of insulin analogs do
not increase cancer risk [10]. Long-term use or high
dose of insulin glargine may significantly increase the
risk of breast cancer [11–14]. Therefore insulin glar-
gine may have different effects on cancer development
compared to other forms of insulin.
Insulin glargine was the first insulin analog introduced
into the market of Taiwan in February 2004, but human
insulin remains the most commonly used insulin in clin-
ical practice. Therefore, it is clinically important to clarify
whether human insulin can be associated with breast
cancer. The purpose of the present study was to evaluate
whether human insulin use without confounding exposure
to insulin analogs would increase the risk of breast cancer
in female patients with type 2 diabetes mellitus, by using
the National Health Insurance (NHI) databases of Taiwan.
The reasons for precluding the investigation of the effect
of insulin glargine in the present study is due to the obser-
vation in clinical practice that most users of insulin might
have been prescribed human insulin for a while before
being given insulin glargine or might have been treated
with a combination of human insulin and insulin analogs,
making it difficult to dissect an effect of insulin glargine
independent of human insulin. Additionally, the shorter
duration of exposure to insulin glargine in most patients
and the small number of cases prescribed insulin glargine
during the study period would lead to a lack of sufficient
statistical power for subgroup analyses in the study.Methods
This is a nationwide cohort analysis using the NHI data-
bases including all patients with a diagnosis of diabetes
mellitus during the period from 1996 to 2009 in Taiwan.
The study was approved by an ethic review board of the
National Health Research Institutes with registered
approval number 99274. Written informed consent from
the participants was not required according to local
regulations because the identification information of the
individuals was scrambled and de-identified prior to ana-
lysis for the protection of privacy.
Since March 1995 a compulsory and universal system
of health insurance (the so-called NHI) was imple-
mented in Taiwan. All contracted medical institutes
must submit computerized and standard claim docu-
ments for reimbursement. More than 99 % of citizens
are enrolled in the NHI, and >98 % of the hospitals
nationwide are under contract with the NHI. The aver-
age number of annual physician visits in Taiwan is one
of the highest around the world, at approximately 15
visits per year per capita in 2009.
The National Health Research Institutes is the only
organization approved, as per local regulations, for
handling the NHI reimbursement databases for academic
research. The databases contain detailed records on every
visit for each patient, including outpatient visits, emer-
gency department visits and hospital admission. The data-
bases also include principal and secondary diagnostic
codes, prescription orders, and claimed expenses.
The identification information of the individuals was
de-identified for the protection of privacy. Diabetes was
coded 250.XX and breast cancer 174, based on the
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM).
The entry date was set on 1 January 2004. The selec-
tion of this entry date was due to the fact that insulin
glargine or other insulin analogs were not available
before this date in Taiwan. Therefore at the time of
enrollment, all patients would not have been exposed to
insulin glargine or other insulin analogs. Patients who
might happen to be prescribed insulin glargine or other
insulin analogs after the entry date were censored on the
date of their prescriptions as mentioned later in the
calculation of person-years of follow-up. These proce-
dures assured that none of the patients were exposed to
insulin glargine or other insulin analogs during follow-
up in either the human insulin ever-users or never-users
defined in the study.
We first retrieved the databases of all patients who had
been diagnosed as having diabetes and under treatment
with either oral antidiabetic drugs (OAD) or insulin dur-
ing the period of 1996–2009 from the whole nation and
who remained in the insurance program after the entry
date (n = 1,557,468). After excluding men (n = 930,327),
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2004 (n = 534,522), patients who held a Severe Morbidity
Card as having type 1 diabetes (n = 5,894, in Taiwan,
patients with type 1 diabetes were issued a so-called
“Severe Morbidity Card” after certified diagnosis and they
were waived for much of the co-payments), patients hav-
ing a diagnosis of breast cancer before 2004 (n = 11,969),
those who died (n = 62,176) or withdrew from the NHI
(n = 9,512) before entry date, duplicated identification
number (n = 106), unclear information on date of birth
or sex (n = 5,122), and patients who had been pre-
scribed insulin only once (n = 70,151, some patients
might have been given insulin temporarily for certain
medical conditions but they might not be real cases of
diabetes), a total of 482,065 female patients with a diag-
nosis of type 2 diabetes mellitus and under therapy
with OAD or insulin were recruited. A total of 32
patients who had been prescribed insulin during the
first year (i.e., 1996) of the availability of NHI database
were further excluded to assure the accuracy in the
calculation of the dose–response parameters of insulin
exposure as described below.
Those who had ever been prescribed insulin before
entry date were defined as ever-users (n = 59,798,
12.4 %); and never-users (n = 422,235, 87.6 %) were
defined as those who had never been prescribed insulin
before entry date. To evaluate whether a dose–response
relationship could be seen between human insulin and
breast cancer, tertile cutoffs for the following three vari-
ables were used: time since starting human insulin in
months, cumulative duration of human insulin therapy
in months and cumulative dose of human insulin in
units, were calculated from the databases and used for
analyses [15, 16].
All comorbidities and covariates were determined as a
status/diagnosis before the entry date. The ICD-9-CM
codes for the comorbidities were [17]: obesity 278,
nephropathy 580–589, hypertension 401–405, chronic
obstructive pulmonary disease (a surrogate for smoking)
490–496, cerebrovascular disease 430–438, ischemic
heart disease 410–414, peripheral arterial disease 250.7,
785.4, 443.81 and 440–448, eye disease 250.5, 362.0, 369,
366.41 and 365.44, dyslipidemia 272.0-272.4, congestive
heart failure 398.91, 402.11, 402.91, 404.11, 404.13,
404.91, 404.93 and 428, and cancer other than breast
cancer 140–208 (excluding 174). Medications included
pioglitazone, rosiglitazone, sulfonylurea, meglitinide, met-
formin, acarbose, statin, fibrate, angiotensin converting
enzyme inhibitor and/or angiotensin receptor blocker
(ACEI/ARB), calcium channel blocker, non-steroidal anti-
inflammatory drugs and estrogen. Baseline characteristics
between ever-users and never-users of human insulin
were compared by Student’s t test for age and diabetes
duration and by Chi-square test for other variables.The incidence density of breast cancer was calculated
for ever-users and never-users and for different subgroups
of exposure. The numerator for the incidence was the
number of patients with incident breast cancer during the
6-year follow-up (from 1 January 2004 to 31 December
2009), and the denominator was the person-years of
follow-up. For ever-users, the follow-up duration was
either censored at the date of initiation of insulin glargine
or other insulin analogs, or breast cancer diagnosis or at
the date of the last record of the available reimbursement
databases in individuals without incident breast cancer.
For never-users, the follow-up was censored at the date of
insulin initiation (including human insulin or insulin
analogs) or breast cancer diagnosis or the last reimburse-
ment record, depending on whichever occurring first. This
ensured no exposure to insulin of any form throughout
the whole follow-up period until censor in the referent
group of never-users; and no exposure to insulin glargine
or other insulin analogs in the group of ever-users of
human insulin.
Cox proportional hazards regression was performed to
estimate the hazard ratios for breast cancer for ever-users
versus never-users, and for the various subgroups of
dose–response parameters based on the tertile cutoffs
using never-users of human insulin as the referent group.
The models were adjusted for all variables compared pre-
viously as baseline characteristics between ever-users and
never-users (primary model). In all regression models, age
and diabetes duration (logarithmically transformed to
normalize the data) were treated as continuous variables.
To examine whether the results might be consistent
under different conditions, the following models were
conducted as sensitivity analyses: 1) adjusting only for
the following important risk factors of breast cancer:
age, diabetes duration, obesity, estrogen, metformin,
statin and ACEI/ARB (sensitivity model I); and 2)
including human insulin exposure post entry date but
prior to breast cancer diagnosis in the calculation of
the dose–response parameters.
Some medications commonly used in patients with
diabetes such as metformin [18, 19], statin [20] and
ACEI/ARB [21, 22] may affect the risk of breast can-
cer. In order to evaluate the potential risk modifica-
tion by these medications with short- or long-term
exposure, additional Cox regression models were cre-
ated by categorizing the patients into various groups
of exposure to insulin and to these medications for
<2 years or ≥ 2 years. In consideration that some
medications might be used after the entry date, the
exposure duration to insulin and the other medica-
tions were calculated until censor.
Analyses were conducted using SAS statistical soft-
ware, version 9.3 (SAS Institute, Cary, NC). P < 0.05 was
considered statistically significant.
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Table 1 compares the baseline characteristics between
ever-users (n = 59,798) and never-users (n = 422,235) of
human insulin. All variables differed significantly be-
tween the two groups. Ever-users are characterized by
older age, longer diabetes duration, higher proportions
of all comorbidities and other cancer, and higher propor-
tions of using other medications.
Table 2 shows the incidences of breast cancer between
ever-users and never-users of human insulin, and among
the different tertiles of the dose–response parameters of
human insulin exposure. In the primary model, the
overall hazard ratio (1.033, 95 % confidence interval:
0.936-1.139) for ever-users versus never-users was not
statistically significant, but a significantly higher risk
was observed in the third tertiles of all three dose–
response parameters. Similar findings were noted in
sensitivity model I where only a subset of important
risk factors of breast cancer was adjusted for. Add-
itionally, a significantly lower risk of breast cancer
was observed for the first tertiles of cumulative dose
and cumulative duration of exposure. In sensitivity
model II where human insulin exposure post entry
date but prior to breast cancer diagnosis was also
included in the calculation of the dose–response
parameters, significantly higher risk of breast cancer
was still observed in the third tertiles of time since
starting human insulin and cumulative duration of
human insulin exposure, and in the second tertile of
cumulative dose of human insulin.
Table 3 shows the results of the models that consid-
ered the potential risk modification by the use of other
medications. In Model I, patients treated with human
insulin alone without any OAD had a significantly
higher risk of breast cancer (hazard ratio: 1.413, 95 %
confidence interval: 1.030-1.940). On the other hand, pa-
tients treated with OAD with a short duration of insulin
treatment for <2 years had a significantly lower risk,
while the risk became neutral in those who had been
treated with OAD plus human insulin for ≥2 years.
Model II suggested that human insulin users who also
had been treated with metformin for ≥2 years had a
significantly lower risk of breast cancer (hazard ratio:
0.798, 95 % confidence interval: 0.741-0.859). Model III
suggested that human insulin users who also had been
treated with statin for as short as <2 years had a signifi-
cantly lower risk of breast cancer. The beneficial effect
seemed to persist in patients who had used statin for a
longer duration of ≥2 years. In Model IV, human
insulin users without use of ACEI/ARB or with a short-
term use of ACEI/ARB for <2 years had a significantly
lower risk of breast cancer, while those who had been
treated with ACEI/ARB for a longer term (≥2 years)
showed a neutral risk association.Discussion
The findings of this large population-based study sug-
gested that prolonged exposure to human insulin may
increase the risk of breast cancer after multivariable
adjustment (Table 2). Significantly higher risk of approxi-
mately 25 % can be consistently observed in the third ter-
tile of a cumulative duration of human insulin exposure
≥21.8 months in all three models including the primary
model and the two sensitivity models (Table 2). The
increased risk can be as high as 40 % in a subset of
patients who had been treated with insulin alone without
the use of any OAD (Model I, Table 3). Additional ana-
lyses suggested that the risk of breast cancer associated
with human insulin use might be modified by a combin-
ation use of other medications including metformin, statin
and ACEI/ARB (Models II to IV, Table 3).
Insulin per se may be able to increase the risk of
breast cancer through several mechanisms. First, insulin
is a well-known growth factor, which may activate the
proliferation of breast cancer cells through its inter-
action with the insulin receptor or the IGF-1 receptor
[23] and through activating the mTOR pathway [5].
Second, exogenous insulin administration is always
followed by increased body weight, which is a key
feature leading to insulin resistance, hyperinsulinemia,
hyperglycemia, increased oxidative stress and proinflam-
mation. All of these can contribute to the increased risk
of various types of cancer in epidemiological studies
[24–27]. Third, clinically it is not easy to obtain optimal
physiological level of insulin to sustain glycemic control
by exogenous insulin administration and therefore
hyperinsulinemia is unavoidable in the presence of
insulin resistance, leading to a vicious cycle favoring the
development of breast cancer.
Diabetes severity may be a prime driver of breast
cancer risk, and insulin is always used at a late stage of
diabetes when pancreatic β cells are exhausted and most
OAD fail to adequately control blood glucose. Therefore,
indication bias may exist when insulin is used in patients
having more comorbidities and using more concomitant
drugs that may also affect the risk of breast cancer. In
the present study, although most comorbidities and
medications that may be related to the exposure to
human insulin and/or to breast cancer have been
considered as potential confounders (Tables 1, 2 and 3),
it was not able to neatly segregate the confounding
effect of other indicators of diabetes severity such as gly-
cemic control, which might also be highly correlated
with the use of insulin, from the effect of insulin per se.
All of the indicators of disease severity may also progress
in intensity with respect to the length of diabetes dur-
ation and thus to the duration of insulin exposure.
Therefore, a link between the dose–response parameters
of insulin use might also reflect a link with progressive
Table 1 Baseline characteristics between never-users and ever-users of human insulin
Human insulin
Variables Never-users Ever-users P value
n % n %
n = 482033 422235 59798
Age (years)a 62.54 ± 12.22 63.70 ± 12.65 <0.0001
Diabetes duration (years)a 5.12 ± 2.52 7.12 ± 1.65 <0.0001
Obesity 6082 1.44 974 1.63 0.0003
Nephropathy 39290 9.31 19533 32.66 <0.0001
Hypertension 228224 54.05 46172 77.21 <0.0001
Chronic obstructive pulmonary disease 51257 12.14 16773 28.05 <0.0001
Cerebrovascular disease 51910 12.29 19239 32.17 <0.0001
Ischemic heart disease 86668 20.53 25673 42.93 <0.0001
Peripheral arterial disease 41898 9.92 17216 28.79 <0.0001
Eye disease 48952 11.59 17588 29.41 <0.0001
Dyslipidemia 182015 43.11 33585 56.16 <0.0001
Congestive heart failure 24242 5.74 11009 18.41 <0.0001
Other cancer prior to baseline 39359 9.32 7672 12.83 <0.0001
Pioglitazone 9581 2.27 3503 5.86 <0.0001
Rosiglitazone 38135 9.03 16488 27.57 <0.0001
Sulfonylurea 304121 72.03 54487 91.12 <0.0001
Meglitinide 27501 6.51 11588 19.38 <0.0001
Metformin 259203 61.39 53420 89.33 <0.0001
Acarbose 33979 8.05 14763 24.69 <0.0001
Statin 97657 23.13 23400 39.13 <0.0001
Fibrate 77010 18.24 19220 32.14 <0.0001
Angiotensin converting enzyme
inhibitor/angiotensin receptor blocker
169738 40.20 41504 69.41 <0.0001
Calcium channel blocker 133391 31.59 34541 57.76 <0.0001
Non-steroidal anti-inflammatory drugs 286403 67.83 56369 94.27 <0.0001
Estrogen 37775 8.95 8583 14.35 <0.0001
aAge and diabetes duration are expressed as mean ± standard deviation
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diabetes duration such as insulin resistance, inflamma-
tion, oxidative stress, and aggravated hyperglycemia. It is
true that diabetes per se may increase the risk of breast
cancer, disregarding the use of insulin, as observed in a
recent Danish study [28], suggesting a possible link
through some underlying features of diabetes and not
through exogenous insulin administration. However this
Danish study fell short of a lack of dose–response
analysis, being unable to differentiate the use of human
insulin and insulin glargine, and a lack of adjustment for
potential confounders. Actually if we did not consider
the dose–response analyses, the overall hazard ratio was
not significant (Table 2).
Some studies suggested that patients using insulin
glargine may have a higher risk of cancer than patientsusing human insulin [10]. However, a recent analysis
including 31 randomized clinical trials did not find a
higher incidence of cancer, including breast cancer, in
patients using insulin glargine in comparison to compar-
ators [29]. In the present study, the possibility of expos-
ure to insulin glargine or other insulin analogs had been
excluded in the calculation of the person-years during
the follow-up. Therefore, whether insulin glargine may
increase breast cancer risk in our population is an issue
awaiting further confirmation.
Taken together, although the present study demon-
strated a link between prolonged use of human insulin
and breast cancer risk, it was not able to clearly discern
the cause-effect relationship due to the inherent bias
across the two groups of patients featuring a potential
direct impact of diabetes severity on breast cancer risk.
Table 2 Exposure to human insulin and incidences of breast cancer and the adjusted hazard ratios comparing exposed to unexposed
Exposure to
human insulin
Case number Incident breast
cancer
% Person-years Incidence rate
(per 100,000
person-years)
Primary model Sensitivity model I Sensitivity model II
HR 95 % CI P HR 95 % CI P HR 95 % CI P
Never-users 422235 4711 1.12 2190014.8 215.1 1.000 1.000 1.000
Ever-users 59798 559 0.93 268941.3 207.9 1.033 (0.936-1.139) 0.5200 0.994 (0.907-1.090) 0.9013 1.033 (0.936-1.139) 0.5200
Time since starting human insulin (months)
Never-users 422235 4711 1.12 2190014.8 215.1 1.000 1.000 1.000
<35 19409 165 0.85 88579.0 186.3 0.924 (0.787-1.085) 0.3358 0.877 (0.750-1.027) 0.1024 0.924 (0.787-1.085) 0.3358
35-67 19817 173 0.87 89856.1 192.5 0.988 (0.843-1.158) 0.8813 0.944 (0.809-1.101) 0.4603 0.988 (0.843-1.158) 0.8813
≥67 20572 221 1.07 90506.3 244.2 1.185 (1.026-1.368) 0.0209 1.161 (1.011-1.333) 0.0342 1.185 (1.026-1.368) 0.0209
Cumulative dose of human insulin exposure (units)
Never-users 422235 4711 1.12 2190014.8 215.1 1.000 1.000 1.000
<4,000 19106 151 0.79 89076.3 169.5 0.872 (0.738-1.030) 0.1069 0.819 (0.695-0.965) 0.0169 0.982 (0.837-1.152) 0.8264
4,000-39,000 20322 170 0.84 89166.3 190.7 0.960 (0.818-1.126) 0.6148 0.919 (0.787-1.073) 0.2863 1.184 (1.017-1.380) 0.0298
≥39,000 20370 238 1.17 90698.7 262.4 1.260 (1.096-1.450) 0.0012 1.239 (1.084-1.416) 0.0017 0.961 (0.828-1.115) 0.5987
Cumulative duration of human insulin exposure (months)
Never-users 422235 4711 1.12 2190014.8 215.1 1.000 1.000 1.000
<2.8 19751 151 0.76 90689.0 166.5 0.855 (0.724-1.009) 0.0643 0.809 (0.687-0.953) 0.0112 0.855 (0.724-1.009) 0.0643
2.8-21.7 19716 167 0.85 87633.9 190.67 0.981 (0.834-1.153) 0.8142 0.927 (0.792-1.084) 0.3407 0.981 (0.834-1.153) 0.8142
≥21.8 20331 241 1.19 90618.4 266.0 1.257 (1.094-1.446) 0.0013 1.240 (1.085-1.416) 0.0015 1.257 (1.094-1.446) 0.0013
HR: hazard ratio, CI: confidence interval
Primary model: adjusted for all variables listed in Table 1.
Sensitivity model I: adjusting only for important risk factors of breast cancer including age, diabetes duration, obesity, estrogen, metformin, statin and angiotensin converting enzyme inhibitor/angiotensin
receptor blocker.










Table 3 Models considering the potential risk modification on the link between human insulin and breast cancer by other medications
commonly used in patients with type 2 diabetes mellitus
Model n/N HR 95 % CI P
Model I
Never users of insulin 4165/345654 1.000
Users of human insulin alone without any OAD 39/2939 1.413 (1.030-1.940) 0.0323
OAD plus human insulin < 2 years 636/88019 0.728 (0.668-0.793) <0.0001
OAD plus human insulin≥ 2 years 430/45421 0.983 (0.882-1.096) 0.7587
Model II
Never users of insulin 4165/345654 1.000
Users of human insulin alone or plus OAD excluding metformin 82/7827 1.127 (0.904-1.405) 0.2893
Users of human insulin plus metformin < 2 years 23/2285 0.782 (0.519-1.178) 0.2398
Users of human insulin plus metformin ≥ 2 years 1000/126267 0.798 (0.741-0.859) <0.0001
Model III
Never users of insulin 4165/345654 1.000
Users of human insulin plus without use of statin 442/51396 0.928 (0.839-1.027) 0.1484
Users of human insulin plus statin < 2 years 63/8601 0.654 (0.509-0.840) 0.0009
Users of human insulin plus statin≥ 2 years 600/76382 0.789 (0.718-0.866) <0.0001
Model IV
Never users of insulin 4165/345654 1.000
Users of human insulin plus without use of ACEI/ARB 223/26367 0.822 (0.716-0.943) 0.0052
Users of human insulin plus ACEI/ARB < 2 years 492/69952 0.745 (0.675-0.822) <0.0001
Users of human insulin plus ACEI/ARB≥ 2 years 390/40060 1.005 (0.895-1.128) 0.9370
n: case number of incident breast cancer, N: case number followed
HR: hazard ratio, CI: confidence interval
OAD: oral antidiabetic drug, ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker
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insulin effect on breast cancer development and the rela-
tionship featuring a lack of association during the initial
period of insulin use and the requirement of an adequate
incubation period for a significant risk (Table 2), a
carcinogenic effect of prolonged use of human insulin
on breast tissue could not be completely excluded. The
finding of a significant link between insulin use for 3 or
more years and mortality from breast cancer in a recent
follow-up of a large cohort of female patients in Taiwan
[24] adequately reflects a close link between insulin use
for approximately 2 years and breast cancer risk (Table 2)
as shown in the present study.
Metformin is commonly used among the studied
patients (Table 1) and it has been shown to reduce the
risk of breast cancer in previous studies [18, 19]. This
beneficial effect of metformin could also be demon-
strated in the present study (Model II, Table 3). It is
clearly demonstrated here that patients who had used
only human insulin without the use of any other OAD
might suffer from a significantly higher risk of breast
cancer with an estimated hazard ratio of 1.413 (95 %
confidence interval: 1.030-1.940), while those who had
used OAD plus a short-term human insulin use of<2 years might have a significantly lower risk of breast
cancer (Model I, Table 3). However, when human insulin
had been used for a prolonged duration of ≥ 2 years in
addition to OAD, the lower risk observed in the previous
group attenuated and became neutral (Model I, Table 3).
The lower risk associated with OAD when human insulin
had been used for <2 years (Model I, Table 3) might reflect
a beneficial effect of metformin (Model II, Table 3), which
was a commonly used OAD (Table 1).
The analysis in Model III of Table 3 also suggested a
beneficial effect of statin after a short duration of its use
for <2 years, which persisted after a prolonged duration
of ≥2 years. Hypercholesterolemia may accelerate breast
tumor growth in mice [30], probably through the
interaction between 27-hydroxycholesterol (a primary
metabolite of cholesterol) and the estrogen receptor and
liver X receptor [31]. A recent UK study also suggested
that hypercholesterolemia may possibly increase the risk
of breast cancer in humans [32]. Therefore, it is not
known whether the lower risk associated with statin use
could be due to the biological effects of statin per se or
due to an effective reduction in serum cholesterol level
associated with statin use. It is worthy to point out that
even though highly lipophilic statin, such as simvastatin,
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breast cancer risk [33], there is a debate with regards to
an increased risk of breast cancer associated with statin
use, especially among the elderly [34].
The association between ACEI/ARB and breast cancer
risk has been controversial. While some studies suggested
a lack of association [35, 36], a study conducted in Taiwan
suggested a lower risk of breast cancer associated with the
use of ACEI [37] and another study conducted in Turkey
suggested that patients with breast cancer who used
ACEI/ARB might have a lower risk of recurrence and
disease progression [38]. On the other hand, studies
conducted in Taiwan [36] and in the USA [39] suggested a
likely risk association with another class of antihyperten-
sive drugs, the calcium channel blockers. ACEI/ARB are
considered the first-line antihypertensive treatment in
patients with diabetes, but a combination therapy with a
calcium channel blocker, which is more potent in blood
pressure lowering, is always required in diabetic patients
with long-term hypertension. Taking into consideration
the algorithm of the use of antihypertensive agents in the
diabetic patients, patients not using ACEI/ARB in the
present study might mainly represent those without
hypertension and patients who had been using ACEI/ARB
for <2 years might represent those with hypertension for a
short period of time. On the other hand, diabetic patients
who had been treated with ACEI/ARB for 2 or more years
might have represented those with a long-term hyperten-
sion in whom a combination therapy with a calcium chan-
nel blocker is always necessary. Therefore, the attenuation
of the beneficial effect of ACEI/ARB in patients who had
been using these agents for ≥2 years (Model IV, Table 3)
might also be explained by the effect of other antihyper-
tensive agents added on top of ACEI/ARB such as calcium
channel blockers. It should be admitted that the present
study was not aimed at evaluating the risk of breast cancer
associated with antihypertensive treatment and therefore
further studies are necessary to clarify the risk association
of breast cancer with the various classes of antihyperten-
sive agents.
Obesity, reproductive factors and hormone use have
been identified as risk factors of breast cancer [40–42].
In the present study a diagnosis of obesity and the use of
estrogen had been included as potential confounders,
but information of reproductive factors was not available
in the NHI database. It should be pointed out that the
prevalence of obesity was much underestimated in either
the ever-users or never-users of insulin by using a diagno-
sis of obesity as a surrogate (Table 1). In a previous epide-
miologic survey, the prevalence of obesity in patients with
diabetes was 33.5 % and 7.1 %, respectively, by using a body
mass index cutoff of ≥25 and ≥30 kg/m2 [43]. Therefore, a
residual confounding of obesity could not be excluded in
the present study. The lack of adjustment for reproductivefactors might probably exert negligible confounding effect
because a confounder needs to be associated with both
exposure and disease, and should not be an intermediate
variable in the causal pathway [44]. There is probably no
evidence to suggest a link between reproductive factors
and insulin use.
This study has several strengths. The databases included
all claim records on outpatient visits, emergency depart-
ment visits and hospital admission, and we caught the
diagnoses from all sources. Cancer is considered a severe
morbidity by the NHI and most medical co-payments can
be waived. Furthermore, there is a low drug cost-sharing
required by the NHI and patients with certain conditions
such as low-income household, veterans or patients with
prescription refills for chronic disease are exempted from
the drug cost-sharing [45]. Therefore the detection rate of
breast cancer would not tend to differ among different
social classes. The use of medical record also reduced the
potential bias related to self-reporting. Furthermore, we
excluded patients with type 1 diabetes mellitus to demon-
strate a link with type 2 diabetes mellitus; and excluded
the potential contamination of the use of insulin glargine
or other insulin analogs to demonstrate a link with
human insulin. Because the databases were derived
from the whole population, another important strength
was an exclusion of potential selection bias related to
sampling error.
Study limitations included a lack of actual measurement
data of confounders such as obesity, smoking, alcohol
drinking, family history, lifestyle, diet, reproductive factors
and genetic parameters. In addition, we did not have
biochemical data such as blood glucose level, insulin, or
C-peptide for evaluating their impact. Finally, the present
study was not able to evaluate the histological patterns,
molecular markers (such as the expression of estrogen
receptor) or clinical stages of breast cancer. According to
the Taiwan Cancer Registry, 88.7 % of all cases with breast
cancer may have invasive ductal carcinoma [46]. There-
fore the breast cancer in the present study might reason-
ably be related to this histological type. Although
misclassification of breast cancer might occur, such a
probability was low because labeled diagnoses should be
printed out in all prescriptions handed to the patients.
Mislabeling of a cancer diagnosis would not be acceptable
to the patients when they saw the diagnosis.
Conclusions
The present study reveals a significantly higher risk of
breast cancer associated with prolonged use of human
insulin in female patients with type 2 diabetes mellitus.
Such a risk can be consistently demonstrated when cumu-
lative duration of human insulin exposure is ≥21.8 months.
However, whether such an effect is independent of disease
severity, which is highly correlated with the use of insulin,
Tseng BMC Cancer  (2015) 15:846 Page 9 of 10remains to be clarified. The link between human insulin
can also be beneficially modified by a combination therapy
with metformin, statin or ACEI/ARB. Whether insulin
glargine or other insulin analogs may increase the
risk of breast cancer is not evaluated in the present
study, but this can be an important issue worthy of
further investigation.
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